Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
$26m mcap
https://money.tmx.com/en/quote/ASND
Thank you for the tip
Thanks for sharing MM. Is it common for Covid clinical trials to include Neutrophil in their exploratory objectives? I guess if not, they will have to rely on the data from SFX-01 which includes this dataset.
presuming this has been posted before but just in case it has not.
https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003486-19/GB
A very interesting research project announced today by University of Dundee on their focus on the roll of of neutrophils and the harmful inflammation effects of Covid-19, which must add weight to SFX-01's anti-inflammatory properties and interestingly enough "Neutrophil functional studies in isolated cells" are part of the Exploratory objectives of SFX-01 Covid/Ards trial at University of Dundee, and so the timing could be viewed as encouraging??? Gla :-)
https://www.dundee.ac.uk/stories/project-investigate-blood-vessel-damage-covid-19-patients
and Prof Chalmers is still looking to expand his department which could also be viewd as an encouraging sign. ;-)
James D Chalmers
@ProfJDChalmers
·
10 May
Just two days left to apply for our technician post
Who wouldn't want to work on epithelial biology in lung disease?
Come and join us!
https://jobs.dundee.ac.uk/fe/tpl_uod01.a
An opportunity has arisen for a research technician to support our internationally leading Lung Infection laboratory at the University of Dundee. The group studies a range of lung infections including COPD, bronchiectasis and COVID-19.
You will be expected to provide high quality technical assistance to Professor Chalmers, Dr Shoemark and the other members of the research team. Core tasks will include processing biological samples, culture of airway epithelial cells at air liquid interface, cell culture experiments, microscopy and generation of experimental data using methods such as ELISA.
You will support the principal investigators, post-docs and PhD students as part of a multidisciplinary team, performing laboratory research to a high standard, organising study data and supervising undergraduates. You will work collaboratively with team members to support multiple ongoing research studies with a focus on the role of motile cilia in chronic lung disease.
As On target has correctly pointed out, it's not just the primary objectives under assessment, the secondary objectives and especially the exploratory objectives will be highly significant to proceedings imho, and no doubt will add time to Prof Chalmers efficacy assessment for the publication of any detailed and comprehensive report, and as so the fact that we're still waiting for results suggests that there could be something encouraging....fingers crossed...Gla :-)
The trial will test the following hypothesis:
Treatment with SFX-01 in addition to standard care will be superior to placebo plus standard care in achieving improved clinical status in patients initially hospitalized with community acquired pneumonia (including patients investigated for suspected COVID19 infection).
.........................
Primary objective:
To evaluate the clinical efficacy of SFX-01 compared to placebo on top of standard care in adult patients initially hospitalized with community acquired pneumonia. Outcome measure:7 point ordinal scale measured on Day 15.
Secondary Objectives:
Evaluate the clinical efficacy of SFX-01 relative to standard care in adult patients hospitalized with suspected COVID-19
Evaluate the safety of the intervention through 28 days of follow-up as compared to the control arm
Outcome measures:
Cumulative incidence of serious Adverse events (SAEs)
Discontinuation or temporary suspension of treatment
..............................
Exploratory objectives (All sites)
Biofire analysis of nasal swab or sputum sample
Subanalysis of outcomes according to the causative pathogen
Exploratory objectives (TAYSIDE ONLY)
Analysis of Nrf2 pathway activity in isolated peripheral blood mononuclear cells
Neutrophil functional studies in isolated cells
Measurement of interleukin-6, interleukin-1 beta and TNF-alpha in blood
https://star-covid19.com/
Correct.
Good point my maths is ****!!!!!
Ok so that was kind of my point that we were late but I’ve got it wrong so should be soon if we go off same sort of time scales assuming nothing is too different?
Sorry 7.5 weeks.
So same for EVG would be sometime next week.
EVG said Q2.
SNG was about 8.5 weeks:
28/5/20 - 100 patients dosed
20/7/20 - results
Ok so Synairgen last person dosed to results were 4 weeks?
7 weeks counting seems to be a long time, was there any time given in any of the RNS?
It's a very tricky situation at least for me.
My best guess is that there is something encouraging from the trial and that they are taking their time to carry out a detailed analysis and tweak the remaining recruitment accordingly.
If anything positive emerges there is tremendous potential to explode upside from the low market cap we sit in, so it is tempting to add further. But I already have a considerable stake so don't want to add any further at least until the news is released.
The SP gradually back down to 7.6p now.. the market seems to be pricing in bad news... hopefully we get a nice surprise soon! Anyone buying in at this time are quite lucky (or not).. I bought from around 10p+ averaging all the way down.
Data
7th week of assessing the data or patients?
Cheers Kenneth.
After the 100th patient was recruited in Feb there is then a 15 day treatment period followed by another 28 day observation period, which takes us until around the end of March until the assessment could begin.
So I think we're in the 7th week of assessment, assuming they started it straight away.
There were a lot of secondary and other objectives as well as the primary ones so I guess a lot to assess.
My dads ok Thank you.
He pulled through but got gully ian Barr syndrome either by COVID or the vaccine, it was touch and go.
He didn’t get the SFX treatment in the end as he had to come back to Dundee we very few days which was a 40 mile round trip at 85.
All patients have been recruited and final dosesd in Feb I believe, the readout of results are way over due? It should only take a few weeks fir readout.
Not that i know much about clinical trials but i,m also thinking the longer without news the better.
"The term 'futility' is used to refer to the inability of a clinical trial to achieve its objectives. In particular, stopping a clinical trial when the interim results suggest that it is unlikely to achieve statistical significance can save resources that could be used on more promising research."
Thinking they have long enough to conclude on this.
No news is good news I reckon, and I'm sure Huw would want any bad news out of the way by now so he could get on with updating the market on the rest of the pipeline, and Prof Chalmers appears to be an incredibly busy bloke , and so a comprehensive and detailed positive efficacy assessment presumably will take a lot longer than a negative one...Gla :-)
How's your dad Kenneth, did he do well on SFX-01?
Why are the results taking so long???